Brought to you by 
Merck gets ex- N. American rights to Cardiome's oral vernakalant; later gains WW rights; deal ends
Apr 2009
Executive Summary
Cardiovascular therapeutics developer Cardiome Pharma has granted Merck & Co. exclusive rights to its oral version of vernakalant, a Phase III drug candidate for atrial fibrillation (AF). The Merck Sharp & Dohme subsidiary received a global license (excluding the US, Canada, and Mexico) to the intravenous formulation.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Co-Promotion
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck gets ex- N. American rights to Cardiome's oral vernakalant; later gains WW rights; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice